Cancers, Vol. 12, Pages 1650: Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation

Conclusion: BRAFi+MEKi combinations share a similar safety profile attributed to class effects, yet concomitantly, these combinations display distinctive effects that can dramatically impact patients’ health. Owing to the limitations of pharmacovigilance studies, some findings warrant further validation. However, the possibility of an increased risk for these events should be considered in patient care.

Source: Cancers - June 21, 2020 Category: Cancer & Oncology Authors: Tomer Meirson Nethanel Asher David Bomze Gal Markel Tags: Article Source Type: research